Idexx Laboratories logo

Idexx Laboratories share price today

(IDXX)

Idexx Laboratories share price is $418.63 & ₹36,250.43 as on 15 Jan 2025, 2.30 'hrs' IST

$418.63

-3.99

(-0.94%)

Market is closed - opens 8 PM, 15 Jan 2025

View live Idexx Laboratories share price in Dollar and Rupees. Guide to invest in Idexx Laboratories stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Idexx Laboratories, along with analyst recommendations, forecasts, and comprehensive financials.

Idexx Laboratories Key Statistics

in dollars & INR

Previous Close
$422.62
Open
$422.49
Today's High
$423.11
Today's Low
$413.18
Market Capitalization
$34.6B
Today's Volume
$634.7K
Revenue TTM
$3.8B
EBITDA
$1.3B
Earnings Per Share (EPS)
$10.48
PE Ratio
40.33
Profit Margin
22.53%
Quarterly Earnings Growth YOY
0.11%
Return On Equity TTM
59.42%

How to invest in Idexx Laboratories from India?

It is very easy for Indian residents to invest directly in Idexx Laboratories from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Idexx Laboratories stock in both Indian Rupees (INR) and US Dollars (USD). Search for Idexx Laboratories or IDXX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Idexx Laboratories or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Idexx Laboratories shares which would translate to 0.002 fractional shares of Idexx Laboratories as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Idexx Laboratories, in just a few clicks!

Returns in Idexx Laboratories for Indian investors in Rupees

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Idexx Laboratories investment value today

Current value as on today

₹84,831

Returns

₹15,169

(-15.17%)

Returns from Idexx Laboratories Stock

₹19,494 (-19.49%)

Dollar Returns

₹4,325 (+4.33%)

Indian investors sentiment towards Idexx Laboratories

21%

Period: Oct 16, 2024 to Jan 14, 2025. Change in 30 Days versus previous period

Search volume for Idexx Laboratories on INDmoney from India has grown in the last 30 days as on Jan 15, 2025. 21% more investors are searching Idexx Laboratories in the last 30 days versus the previous period.

Indian Mutual Funds that invest in Idexx Laboratories

NameShares HeldChange in Shares% of Assets
Motilal Oswal S&P 500 Index Fund Direct Growth logo
707
-1.28
0.07%
ICICI Prudential NASDAQ 100 Index Fund Direct Growth logo
1057
0.00
0.22%

Global Institutional Holdings in Idexx Laboratories

  • Vanguard Group Inc

    11.85%

  • BlackRock Inc

    11.50%

  • State Street Corp

    4.41%

  • AllianceBernstein L.P.

    3.44%

  • Fundsmith LLP

    3.25%

  • Geode Capital Management, LLC

    2.76%

Analyst Recommendation on Idexx Laboratories

Buy

    68%Buy

    31%Hold

    0%Sell

Based on 19 Wall street analysts offering stock ratings for Idexx Laboratories(by analysts ranked 0 to 5 stars)

Based on 19 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
12
Hold
6
6
6
Sell
0
0
0

Analyst Forecast on Idexx Laboratories

What analysts predicted

Upside of 14.33%

Target:

$478.62

Current:

$418.63

Insights on Idexx Laboratories

  • Price Movement

    In the last 1 year, IDXX stock has moved down by -21.0%
  • Decreasing Revenue

    Idexx Laboratories, Inc. has experienced a decline in revenue over the past two quarters. The revenue decreased from $1.00 billion to $975.54 million, resulting in an average decrease of 2.8% per quarter.
  • Increasing Net Profit

    Idexx Laboratories, Inc. has shown a positive profit trend over the last two quarters. The net profit increased from $203.29 million to $232.84 million, resulting in an average increase of 12.7% per quarter.
  • IDXX vs A (1 yr)

    In the last 1 year, Agilent Technologies Inc. has given 8.7% return, outperforming this stock by 29.7%
  • IDXX vs A (3 yr)

    In the last 3 years, Idexx Laboratories, Inc. has experienced a drawdown of -20.2%, however Agilent Technologies Inc. resisted the overall trend and outperformed by 18.3%
  • Price to Sales

    Idexx Laboratories, Inc. currently has a Price-to-Sales Ratio of 9.1, meaning that investors are willing to pay $9.1 for every $1 of sales the company generates. In comparison, Agilent Technologies Inc. has a lower Price-to-Sales Ratio of 6.4, indicating that investors are willing to pay $6.4 for every $1 of sales. This suggests that investors have a higher valuation of Idexx Laboratories based on its sales compared to Agilent Technologies.

Idexx Laboratories Financials in INR & Dollars

FY18Y/Y Change
Revenue
$2.2B
↑ 12.4%
Net Income
$377.0M
↑ 43.28%
Net Profit Margin
17.04%
↑ 3.68%
FY19Y/Y Change
Revenue
$2.4B
↑ 8.75%
Net Income
$427.7M
↑ 13.44%
Net Profit Margin
17.77%
↑ 0.73%
FY20Y/Y Change
Revenue
$2.7B
↑ 12.45%
Net Income
$581.8M
↑ 36.02%
Net Profit Margin
21.49%
↑ 3.72%
FY21Y/Y Change
Revenue
$3.2B
↑ 18.79%
Net Income
$744.8M
↑ 28.03%
Net Profit Margin
23.17%
↑ 1.68%
FY22Y/Y Change
Revenue
$3.4B
↑ 4.73%
Net Income
$679.1M
↓ 8.83%
Net Profit Margin
20.17%
↓ 3.0%
FY23Y/Y Change
Revenue
$3.7B
↑ 8.72%
Net Income
$845.0M
↑ 24.44%
Net Profit Margin
23.08%
↑ 2.91%
Q2 FY23Q/Q Change
Revenue
$943.6M
↑ 4.83%
Net Income
$224.2M
↑ 4.76%
Net Profit Margin
23.76%
↓ 0.02%
Q3 FY23Q/Q Change
Revenue
$915.5M
↓ 2.98%
Net Income
$212.2M
↓ 5.35%
Net Profit Margin
23.18%
↓ 0.58%
Q4 FY23Q/Q Change
Revenue
$901.6M
↓ 1.52%
Net Income
$194.5M
↓ 8.34%
Net Profit Margin
21.58%
↓ 1.6%
Q1 FY24Q/Q Change
Revenue
$964.1M
↑ 6.93%
Net Income
$235.6M
↑ 21.11%
Net Profit Margin
24.44%
↑ 2.86%
Q2 FY24Q/Q Change
Revenue
$1.0B
↑ 4.1%
Net Income
$203.3M
↓ 13.7%
Net Profit Margin
20.26%
↓ 4.18%
Q3 FY24Q/Q Change
Revenue
$975.5M
↓ 2.79%
Net Income
$232.8M
↑ 14.53%
Net Profit Margin
23.87%
↑ 3.61%
FY18Y/Y Change
Profit
$1.2B
↑ 13.14%
FY19Y/Y Change
Profit
$1.4B
↑ 9.99%
FY20Y/Y Change
Profit
$1.6B
↑ 15.05%
FY21Y/Y Change
Profit
$1.9B
↑ 20.27%
FY22Y/Y Change
Profit
$2.0B
↑ 6.08%
FY23Y/Y Change
Profit
$2.2B
↑ 9.26%
Q2 FY23Q/Q Change
Profit
$572.9M
↑ 5.5%
Q3 FY23Q/Q Change
Profit
$548.0M
↓ 4.34%
Q4 FY23Q/Q Change
Profit
$526.2M
↓ 3.98%
Q1 FY24Q/Q Change
Profit
$593.1M
↑ 12.72%
Q2 FY24Q/Q Change
Profit
$620.9M
↑ 4.69%
Q3 FY24Q/Q Change
Profit
$596.0M
↓ 4.0%
FY18Y/Y Change
Operating Cash Flow
$400.1M
↑ 7.18%
Investing Cash Flow
$138.6M
↓ 199.94%
Financing Cash Flow
$-597.8M
↑ 187.38%
FY19Y/Y Change
Operating Cash Flow
$459.2M
↑ 14.77%
Investing Cash Flow
$-205.5M
↓ 248.29%
Financing Cash Flow
$-286.4M
↓ 52.09%
FY20Y/Y Change
Operating Cash Flow
$648.1M
↑ 41.14%
Investing Cash Flow
$-109.4M
↓ 46.78%
Financing Cash Flow
$-248.4M
↓ 13.27%
FY21Y/Y Change
Operating Cash Flow
$755.5M
↑ 16.59%
Investing Cash Flow
$-293.0M
↑ 167.85%
Financing Cash Flow
$-697.4M
↑ 180.74%
FY22Y/Y Change
Operating Cash Flow
$543.0M
↓ 28.13%
Investing Cash Flow
$-195.4M
↓ 33.32%
Financing Cash Flow
$-370.9M
↓ 46.81%
Q2 FY23Q/Q Change
Operating Cash Flow
$200.3M
↑ 8.92%
Investing Cash Flow
$-27.5M
↓ 30.48%
Financing Cash Flow
$-151.0M
↑ 3.39%

Idexx Laboratories Technicals Summary

Sell

Neutral

Buy

Idexx Laboratories is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Idexx Laboratories Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Idexx Laboratories, Inc. logo
-1.82%
-14.88%
-18.73%
-18.44%
47.87%
Agilent Technologies Inc. logo
3.11%
6.33%
8.75%
1.05%
57.51%
Thermo Fisher Scientific, Inc. logo
4.76%
0.08%
2.49%
-5.86%
63.78%
Danaher Corp. logo
2.43%
-4.53%
5.79%
-16.82%
47.11%
Iqvia Holdings Inc. logo
3.83%
-11.14%
-3.79%
-15.55%
26.7%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Idexx Laboratories, Inc. logo
40.33
40.33
4.4
10.73
0.59
0.23
NA
19.72
Agilent Technologies Inc. logo
31.06
31.06
2.33
5.57
0.25
0.08
0.0
20.53
Thermo Fisher Scientific, Inc. logo
34.02
34.02
2.14
21.69
0.13
0.05
0.0
128.08
Danaher Corp. logo
44.42
44.42
3.2
7.5
0.08
0.04
0.0
71.03
Iqvia Holdings Inc. logo
26.75
26.75
1.07
11.11
0.22
0.05
NA
38.37
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Idexx Laboratories, Inc. logo
Buy
$34.6B
47.87%
40.33
22.53%
Agilent Technologies Inc. logo
Buy
$40.5B
57.51%
31.06
21.75%
Thermo Fisher Scientific, Inc. logo
Buy
$212.5B
63.78%
34.02
14.48%
Danaher Corp. logo
Buy
$173.3B
47.11%
44.42
16.39%
Iqvia Holdings Inc. logo
Buy
$37.1B
26.7%
26.75
9.17%

About Idexx Laboratories

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Organization
Idexx Laboratories
Employees
11000
CEO
Mr. Jonathan J. Mazelsky
Industry
Health Technology

Management People of Idexx Laboratories

NameTitle
Mr. Jonathan J. Mazelsky
President, CEO & Director
Mr. Brian P. McKeon
CFO, Executive VP & Treasurer
Mr. Michael J. Lane
Executive VP and GM Global Reference Laboratories, Diagnostic Solutions & Information Technology
Dr. Nimrata Khatra Hunt P.E., Ph.D.
Executive Vice President Global Strategy & Commercial
Mr. Bob Asmann
Senior Vice President of Global Operations
Mr. Jeffery D. Chadbourne
Senior Vice President of Commercial Finance & Sales Operations
Mr. Ken Grady
Senior VP & Chief Information Officer
Ms. Sharon E. Underberg J.D.
Executive VP, General Counsel, & Corporate Secretary
Ms. Julie Godon
Senior VP & Global Marketing Officer
Mr. Michael P. Johnson
Executive VP & Chief Human Resources Officer

Important FAQs about investing in Idexx Laboratories from India :

What is Idexx Laboratories share price today?

Idexx Laboratories share price today stands at $418.63, Open: $422.49 ; Previous Close: $422.62 ; High: {{1_rba_end}} ; Low: {{1_rba_st}} ; 52 Week High: {{rba_end}} ; 52 Week Low: {{rba_st}}. The stock opens at $422.49, after a previous close of $422.62. The stock reached a daily high of {{1_rba_end}} and a low of {{1_rba_st}}, with a 52-week high of {{rba_end}} and a 52-week low of {{rba_st}}.

Can Indians buy Idexx Laboratories shares?

Yes, Indians can invest in the Idexx Laboratories (IDXX) from India.

With INDmoney, you can buy Idexx Laboratories at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Idexx Laboratories at zero transaction cost.

How can I buy Idexx Laboratories shares from India?

It is very easy to buy Idexx Laboratories from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Idexx Laboratories be purchased?

Yes, you can buy fractional shares of Idexx Laboratories with INDmoney app.

What are the documents required to start investing in Idexx Laboratories stocks?

To start investing in Idexx Laboratories, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Idexx Laboratories

Today’s highest price of Idexx Laboratories (IDXX) is {{1_rba_end}}.

Today’s lowest price of Idexx Laboratories (IDXX) is {{1_rba_st}}.

What is today's market capitalisation of Idexx Laboratories

Today's market capitalisation of Idexx Laboratories IDXX is 34.6B

What is the 52 Week High and Low Range of Idexx Laboratories

  • 52 Week High

    {{rba_end}}

  • 52 Week Low

    {{rba_st}}

What are the historical returns of Idexx Laboratories?

  • 1 Month Returns

    -1.82%

  • 3 Months Returns

    -14.88%

  • 1 Year Returns

    -18.73%

  • 5 Years Returns

    47.87%

Who is the Chief Executive Officer (CEO) of Idexx Laboratories

Mr. Jonathan J. Mazelsky is the current Chief Executive Officer (CEO) of Idexx Laboratories.